Real-world Safety and Effectiveness of Secukinumab in Adult Patients with Moderate to Severe Plaque Psoriasis: Results from Postmarketing Surveillance in Korea

Overview

Journal Ther Adv Chronic Dis

Publisher Sage Publications

Date 2024 Feb 28

PMID 38415046

Authors

Byung Soo Kim

Dong Hyun Kim

Bong Seok Shin

Eun-So Lee

Seong Jin Jo

Chul Hwan Bang

Yeojun Yun

Yong Beom Choe

Affiliations

Soon will be listed here.

Abstract

Background: Secukinumab, a fully human monoclonal antibody, was approved in Korea for the treatment of moderate to severe psoriasis in September 2015.

Objectives: To assess the safety and effectiveness of secukinumab in patients with moderate to severe psoriasis in Korea.

Design: Multicenter, real-world, noninterventional study conducted over 6 years.

Methods: Adults with moderate to severe psoriasis were enrolled. Safety was assessed by evaluating adverse events (AEs), treatment-related AEs, and serious AEs (SAEs). Effectiveness was assessed using the change in absolute Psoriasis Area and Severity Index (PASI) score, percentage of patients achieving PASI 75/90/100 and PASI ⩽2; at weeks 12 and 24.

Results: Overall, 829 and 542 patients were included in the safety and effectiveness sets, respectively. AEs, treatment-related AEs, and SAEs occurred in 29.0%, 9.5%, and 4.1% of patients, with incidence rates of 39.43, 12.98, and 5.59 per 100 patient years, respectively. The absolute PASI score decreased from 16.1 ± 7.1 (baseline) to 1.6 ± 2.4 (week 24), with a similar reduction in biologic-naïve (16.4 ± 7.3 to 1.5 ± 2.2) and biologic-experienced (14.8 ± 5.9 to 2.4 ± 3.2) groups. At week 24, PASI 75/90/100 was achieved by 95.1%, 62.4%, and 24.9% of patients. At week 24, PASI 75/90 were higher in biologic-naïve (96.6%/65.8%) than biologic-experienced patients (88.3%/48.6%), whereas PASI 100 was similar in both cohorts (24.1% and 28.6%). A similar trend in PASI ⩽ 2 was observed in both cohorts.

Conclusion: Secukinumab showed sustained effectiveness and favorable safety profile in adult patients with moderate to severe psoriasis in Korea.

Citing Articles

Secukinumab Causing Medication-Related Osteonecrosis of the Jaw, in a Patient Diagnosed with Psoriasis and Rheumatoid Arthritis.

Hauer L, Moztarzadeh O, Baghalipour N, Gencur J Psoriasis (Auckl). 2024; 14:115-120.

PMID: 39347517 PMC: 11430215. DOI: 10.2147/PTT.S490982.

References

Chodankar D . Introduction to real-world evidence studies. Perspect Clin Res. 2021; 12(3):171-174. PMC: 8323556. DOI: 10.4103/picr.picr_62_21. View

Song H, Park C, Kim T, Choe Y, Lee S, Kim N . The Clinical Profile of Patients with Psoriasis in Korea: A Nationwide Cross-Sectional Study (EPI-PSODE). Ann Dermatol. 2017; 29(4):462-470. PMC: 5500712. DOI: 10.5021/ad.2017.29.4.462. View

Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M . Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence. Clin Cosmet Investig Dermatol. 2022; 15:1649-1658. PMC: 9392468. DOI: 10.2147/CCID.S364640. View

Zhou X, Chen Y, Cui L, Shi Y, Guo C . Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 2022; 13(1):81. PMC: 8786887. DOI: 10.1038/s41419-022-04523-3. View

Armstrong A, Read C . Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020; 323(19):1945-1960. DOI: 10.1001/jama.2020.4006. View

Thaci D, Blauvelt A, Reich K, Tsai T, Vanaclocha F, Kingo K . Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015; 73(3):400-9. DOI: 10.1016/j.jaad.2015.05.013. View

Jung S, Lim S, Jeon J, Heo Y, Choi M, Hong S . Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center. Biomedicines. 2022; 10(5). PMC: 9139155. DOI: 10.3390/biomedicines10051058. View

Paul C, Lacour J, Tedremets L, Kreutzer K, Jazayeri S, Adams S . Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2014; 29(6):1082-90. DOI: 10.1111/jdv.12751. View

Tiburca L, Bembea M, Zaha D, Jurca A, Vesa C, Ratiu I . The Treatment with Interleukin 17 Inhibitors and Immune-Mediated Inflammatory Diseases. Curr Issues Mol Biol. 2022; 44(5):1851-1866. PMC: 9164043. DOI: 10.3390/cimb44050127. View

10.

Ruggiero A, Potestio L, Martora F, Villani A, Comune R, Megna M . Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. Expert Opin Drug Saf. 2023; 22(5):355-362. DOI: 10.1080/14740338.2023.2218086. View

11.

Egeberg A, Ottosen M, Gniadecki R, Broesby-Olsen S, Dam T, Bryld L . Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2017; 178(2):509-519. DOI: 10.1111/bjd.16102. View

12.

Parisi R, Iskandar I, Kontopantelis E, Augustin M, Griffiths C, Ashcroft D . National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020; 369:m1590. PMC: 7254147. DOI: 10.1136/bmj.m1590. View

13.

Fujita H, Ohtsuki M, Morita A, Nagao R, Seko N, Matsumoto K . Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real-world evidence in Japan. J Dermatol. 2020; 48(2):175-183. PMC: 7894540. DOI: 10.1111/1346-8138.15655. View

14.

Schreiber S, Colombel J, Feagan B, Reich K, Deodhar A, McInnes I . Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019; 78(4):473-479. PMC: 6530077. DOI: 10.1136/annrheumdis-2018-214273. View

15.

Galluzzo M, Talamonti M, De Simone C, DAdamio S, Moretta G, Tambone S . Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther. 2018; 18(7):727-735. DOI: 10.1080/14712598.2018.1481503. View

16.

Dastoli S, Passante M, Loconsole F, Mortato E, Balato A, Piccolo V . Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy. J Dermatolog Treat. 2023; 34(1):2200868. DOI: 10.1080/09546634.2023.2200868. View

17.

Blauvelt A, Prinz J, Gottlieb A, Kingo K, Sofen H, Ruer-Mulard M . Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2014; 172(2):484-93. DOI: 10.1111/bjd.13348. View

18.

Kwon S, Lee E . Secukinumab Response in Korean Patients with Moderate to Severe Plaque-Type Psoriasis Irrespective of Previous Biologic Use: 1-Year Experience at a Single Center. Ann Dermatol. 2021; 32(3):255-257. PMC: 7992612. DOI: 10.5021/ad.2020.32.3.255. View

19.

Rompoti N, Sidiropoulou P, Panagakis P, Stratigos A, Papoutsaki M, Stefanaki E . Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response. J Eur Acad Dermatol Venereol. 2020; 34(6):1240-1247. DOI: 10.1111/jdv.16202. View

20.

Parisi R, Symmons D, Griffiths C, Ashcroft D . Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2012; 133(2):377-85. DOI: 10.1038/jid.2012.339. View